

#### The journey ahead

Patrick Ryan

Janssen Research and Development

Columbia University



# OHDSI **OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS**

# **COVID-19 Study-A-Thon** ohdsi.org/covid-19-updates

























































#JoinTheJourney


🕥 /OHDSI



#### Thank you literature review team!












































## Thank you phenotype team!


























#### Thank you network execution team!
























## Thank you characterization team!































## Thank you prediction team!
































#### Thank you estimation teams!































#### Thank you infrastructure support teams!













#### The journey ahead

- Study-a-thon may be finishing today, but this is only the START of our journey today
  - Thanks to Erasmus MC, The MSTeams collaboration platform will continue to be available to support OHDSI collaborations
  - ATLAS-COVID19.ohdsi.org will remain available for collaborative development of analyses
  - Each study team needs to determine their own strategy for dissemination
    - Data.ohdsi.org to make results publicly available as soon as possible
    - Publications to be drafted by the community will be open access



#### Many more important questions need answering...

Name	Question
Alan Goldhammer	Correlation between universal BCG vaccination policy and reduced
	morbidity and mortality for COVID-19
Jeff Hammerbacher	Blood groups of stratified subpopulations of interest
Geert Byttebier	Potential impact of statin use
Rimma Belenkaya	Specific patterns in the lungs as markers of the disease as it develops
	over the course of a week and a half
Michael_Shamberger	Does evidence support that taking anti inflammatories can cause
	adverse outcome?
Sajan Khosla	Length of Stay or 30 Day mortality in patients hospitalized with viral
	pneumonia to understand patterns of antiviral use and potential
	differences in endpoints?
Chiara Attanasio	Clinical use cases on cancer patients in relation with COVID-19
Annalisa Trama	Treatment choices for cancer patients planned for surgery and those
	on cytotoxic chemotherapy or immunotherapy?
Jenny Lane	Compare epidemiological characteristics of the Chinese infections to
	other countries
Evan Minty	Risk of cardiac injuries (e.g. myocarditis) in COVID-19
Vojtech_Huser	Chronic medication stockpiling (preparing for pandemic) by patients
Jason 10033	The role of steroids in COVID-19 ARDS and ventilation management for
	patients
Sara Dempster	COVID-19 mortality in different countries
Ru Cheng	Studying pregnancy and lactation: rate of infection in pregnancy,
	complication rates for pregnant infected women, transmission to
	newborn (especially c-section vs vaginal) and through milk, premature
	birth rates, fetal loss
Michael Kallfelz	Role of coinfection with Varicella Zoster or Epstein Barr

#### Our ask of all of you:

- Keep asking good questions....
  - post your thoughts on the OHDSI forums
- ....and continue to collaborate with each other to help:
  - translate those questions into analysis designs...
  - implement those designs into study packages....
  - execute those packages to generate results....
  - share results across the community to synthesis reliable real-world evidence





We like to thank the large group of community members that worked extremely hard to make these four days possible.

We like to thank the Data Partners that have participated in this effort, and those who will join the journey shortly.

We like to thank you for your active participation in these four days.



#### Questions & Answers





#### Start of a Journey

- This disease isn't stopping yet, and neither will we
- We will remain committed to generating reliable real-world evidence to meet the needs of public health
- Thank you for continuing on the journey with us

